Suppr超能文献

通用毒素筛选在人源细胞中的精确基因组编辑。

Universal toxin-based selection for precise genome engineering in human cells.

机构信息

Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Translational Science and Experimental Medicine, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

出版信息

Nat Commun. 2021 Jan 21;12(1):497. doi: 10.1038/s41467-020-20810-z.

Abstract

Prokaryotic restriction enzymes, recombinases and Cas proteins are powerful DNA engineering and genome editing tools. However, in many primary cell types, the efficiency of genome editing remains low, impeding the development of gene- and cell-based therapeutic applications. A safe strategy for robust and efficient enrichment of precisely genetically engineered cells is urgently required. Here, we screen for mutations in the receptor for Diphtheria Toxin (DT) which protect human cells from DT. Selection for cells with an edited DT receptor variant enriches for simultaneously introduced, precisely targeted gene modifications at a second independent locus, such as nucleotide substitutions and DNA insertions. Our method enables the rapid generation of a homogenous cell population with bi-allelic integration of a DNA cassette at the selection locus, without clonal isolation. Toxin-based selection works in both cancer-transformed and non-transformed cells, including human induced pluripotent stem cells and human primary T-lymphocytes, as well as it is applicable also in vivo, in mice with humanized liver. This work represents a flexible, precise, and efficient selection strategy to engineer cells using CRISPR-Cas and base editing systems.

摘要

原核限制性内切酶、重组酶和 Cas 蛋白是强大的 DNA 工程和基因组编辑工具。然而,在许多原代细胞类型中,基因组编辑的效率仍然很低,这阻碍了基于基因和细胞的治疗应用的发展。迫切需要一种安全的策略来实现精确基因工程细胞的强大和高效富集。在这里,我们筛选了白喉毒素 (DT) 受体的突变体,这些突变体可以保护人类细胞免受 DT 的侵害。选择具有编辑后的 DT 受体变体的细胞可以富集在第二个独立基因座上同时引入的、精确靶向的基因修饰,例如核苷酸取代和 DNA 插入。我们的方法能够在选择基因座上快速产生具有 DNA 盒双等位基因整合的同质细胞群体,而无需克隆分离。基于毒素的选择在癌症转化和非转化细胞中均有效,包括人诱导多能干细胞和人原代 T 淋巴细胞,并且还可在具有人源化肝脏的小鼠体内应用。这项工作代表了一种使用 CRISPR-Cas 和碱基编辑系统工程细胞的灵活、精确和高效的选择策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d8e/7820243/82b368a42491/41467_2020_20810_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验